Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
recombinant human deoxyribonuclease I |
| gptkbp:administeredBy |
nebulizer
|
| gptkbp:approvedBy |
gptkb:FDA
1993 |
| gptkbp:ATCCode |
R05CB13
|
| gptkbp:brand |
Pulmozyme
|
| gptkbp:CASNumber |
143831-71-4
|
| gptkbp:contraindication |
hypersensitivity to dornase alfa
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:hasMolecularFormula |
C1321H1999N345O396S9
|
| https://www.w3.org/2000/01/rdf-schema#label |
dornase alfa
|
| gptkbp:indication |
improving lung function in cystic fibrosis patients
|
| gptkbp:KEGGID |
D03671
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
breaks down DNA in mucus
|
| gptkbp:pregnancyCategory |
B1 (Australia)
|
| gptkbp:product |
gptkb:enzyme
|
| gptkbp:PubChem_CID |
16129697
DB00003 |
| gptkbp:routeOfAdministration |
inhalation
|
| gptkbp:sideEffect |
chest pain
conjunctivitis rash voice alteration pharyngitis |
| gptkbp:storage |
refrigerate at 2–8°C
|
| gptkbp:target |
extracellular DNA
|
| gptkbp:UNII |
Q46YQ6B6FZ
|
| gptkbp:usedFor |
cystic fibrosis
|
| gptkbp:bfsParent |
gptkb:R07AX02
|
| gptkbp:bfsLayer |
7
|